Research programme: small interfering RNA-based therapeutics - Alnylam

Drug Profile

Research programme: small interfering RNA-based therapeutics - Alnylam

Alternative Names: 5 x 15™ programme - Alnylam; ALAS-1 siRNA; ALN ANG; ALN F12; ALN-AAT02; ALN-AC3; ALN-AGT; ALN-APC; ALN-HDV; ALN-HPN; ALN-PDL; ALN-TMP; DLin-MC3-DMA LNP; ESC-GalNAc-Conjugate-HBV

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Charite of Berlin; Sanofi Genzyme; Technical University Munich; University of Heidelberg
  • Class Small interfering RNA
  • Mechanism of Action Alpha 1 antitrypsin inhibitors; Angiotensinogen inhibitors; ANGPTL3 protein inhibitors; Antithrombin III inhibitors; CD274 antigen inhibitors; Factor XII inhibitors; Glycolate oxidase expression inhibitors; Hepcidin inhibitors; Prealbumin inhibitors; RNA interference; TMPRSS6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A; Primary hyperoxaluria
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Adenovirus infections; Alpha 1-antitrypsin deficiency; Amyloidosis; Haemoglobinopathies; Haemophilia; Hepatitis B; Hereditary angioedema; Hyperlipoproteinaemia type V; Hypertriglyceridaemia; Preeclampsia; Primary hyperoxaluria
  • Research Hepatitis; Hepatitis D; Inborn genetic disorders; Liver disorders; Metabolic disorders
  • Suspended Anaemia

Most Recent Events

  • 12 Jun 2017 Alnylam Pharmceuticals receives patent allowance for GalNac conjugation technique in USA
  • 19 Apr 2017 Preclinical trials in Hepatitis B (Combination therapy) in Germany (SC)
  • 19 Apr 2017 Interim pharmacodynamics data from a preclinical study in Hepatitis B presented at the The International Liver Congress 2017 (ILS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top